期刊文献+

Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases 被引量:3

原文传递
导出
摘要 Bile acids(BAs)are the major metabolic product of cholesterol,having detergent-like activities and being responsible for absorption of lipid and lipid-soluble vitamins.Tn addition,it has been increasingly recognized that BAs are important signaling molecules,regulating energy metabolism and immunity.Under physiological circumstances,synthesis and transport of BAs are precisely regulated to maintain bile acid homeostasis.Disruption of bile acid homeostasis results in pathological cholestasis and metabolic liver diseases.During the last decades,BAs have been gradually recognized as an important therapeutic target for novel treatment in chronic liver diseases.This review will provide an update on the current understanding of synthesis,transport and regulation of BAs,with a focus on the therapeutic roles of bile acid signaling in chronic liver diseases.
出处 《Journal of Clinical and Translational Hepatology》 SCIE 2018年第4期425-430,共6页 临床与转化肝病杂志(英文版)
作者简介 Correspondence to:Lun-Gen Lu,Department of Gastroenterology,Shanghai General Hospital,Shanghai Jiaotong University School of Medicine,100 Haining Road,Shanghai 200080,China.Tel:+86-21-63240090,Fax:+86-21-63241377,E-mail:lungenlu1965@163.com
  • 相关文献

参考文献2

二级参考文献48

  • 1Wei Zhong,Zhanxiang Zhou.Alterations of the gut microbiome and metabolome in alcoholic liver disease[J].World Journal of Gastrointestinal Pathophysiology,2014,5(4):514-522. 被引量:9
  • 2Wen-Xing Ding, Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, MS 1018, 3901 Rainbow Blvd, Kansas City, Kansas, KS 66160, United States.Role of autophagy in liver physiology and pathophysiology[J].World Journal of Biological Chemistry,2010,1(1):3-12. 被引量:10
  • 3Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Eng J Med 1994; 330:1342-1347.
  • 4Poupon R, Poupon RE. Treatment of primary biliary cirrhosis.Bailliere's Clin Gastroenterol 2000; 14:615-628.
  • 5Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF,Wheeler DE, Eigenbrodt EH, Munoz SJ, Rubin R, Garcia-Tsao G,Bormer GF, West AB, Boyer J, Luketic VA, Shiffman ML, Mills AS, Peters MG, White HM, Zetterman RK, Rossi SS, Hofman AF,Markin KS. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-766.
  • 6Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD.Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995; 36:935-938.
  • 7Leuschner M, Dietrich CF, You T, Seidl C, Raedle J, Herrmann G, Ackermann H, Leuschner U. Characterization of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000; 46:121-126.
  • 8Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2003; 38:S24-S37.
  • 9Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT,Albers JJ, Jones EA, Brewer Jr B. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985; 89:1266-1278.
  • 10Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW,Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36: 454-458.

共引文献26

同被引文献25

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部